ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för enitociclib. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

14 träffar

Bibliografisk träff 2024-09-01

Discovery and preclinical profile of YK-2168, a differentiated selective CDK9 inhibitor in clinical development.

Liu Y, Xu Z, Hu L, Xia L, Li Q, Zhou W, Chen Y, Li W, Jiang W, Zhu X, Gao X, Xia Y, Zhu Z, Chen S, Ding CZ.

Bioorg Med Chem Lett · journal article · DOI 10.1016/j.bmcl.2024.129941

Bibliografisk träff 2024-06-18

The CDK9 inhibitor enitociclib overcomes resistance to BTK inhibition and CAR-T therapy in mantle cell lymphoma.

Jiang V, Lee W, Zhang T, Jordan A, Yan F, Cai Q, McIntosh J, Vargas J, Liu Y, Wang M.

Biomark Res · letter · DOI 10.1186/s40364-024-00589-7

Bibliografisk träff 2023-12-01

Targeting CDK9 with selective inhibitors or degraders in tumor therapy: an overview of recent developments.

Xiao L, Liu Y, Chen H, Shen L.

Cancer Biol Ther · research support, non-u.s. gov't; review-article; review; journal article · DOI 10.1080/15384047.2023.2219470

Bibliografisk träff 2023-11-01

Enitociclib, a Selective CDK9 Inhibitor, Induces Complete Regression of MYC+ Lymphoma by Downregulation of RNA Polymerase II Mediated Transcription.

Frigault MM, Mithal A, Wong H, Stelte-Ludwig B, Mandava V, Huang X, Birkett J, Johnson AJ, Izumi R, Hamdy A.

Cancer Res Commun · research-article; journal article · DOI 10.1158/2767-9764.crc-23-0219

Bibliografisk träff 2023-08-07

CDK9 INHIBITORS: a promising combination partner in the treatment of hematological malignancies.

Morillo D, Vega G, Moreno V.

Oncotarget · research support, non-u.s. gov't; journal article · DOI 10.18632/oncotarget.28473

Bibliografisk träff 2023-05-26

Predicting and overcoming resistance to CDK9 inhibitors for cancer therapy.

Hu C, Shen L, Zou F, Wu Y, Wang B, Wang A, Wu C, Wang L, Liu J, Wang W, Liu Q.

Acta Pharm Sin B · research-article; journal article · DOI 10.1016/j.apsb.2023.05.026

Bibliografisk träff 2022-11-18

The non-apoptotic function of Caspase-8 in negatively regulating the CDK9-mediated Ser2 phosphorylation of RNA polymerase II in cervical cancer.

Mandal R, Raab M, Rödel F, Krämer A, Kostova I, Peña-Llopis S, Häupl B, Oellerich T, Gasimli K, Sanhaji M, Becker S, Strebhardt K.

Cell Mol Life Sci · research-article; journal article · DOI 10.1007/s00018-022-04598-3

Bibliografisk träff 2022-11-14

VIP152 is a selective CDK9 inhibitor with pre-clinical in vitro and in vivo efficacy in chronic lymphocytic leukemia.

Sher S, Whipp E, Walker J, Zhang P, Beaver L, Williams K, Orwick S, Ravikrishnan J, Walker B, Perry E, Gregory C, Purcell M, Pan A, Yan P, Alinari L, Johnson AJ, Frigault MM, Greer JM, Hamdy A, Izumi R, Mo X, Sampath D, Woyach J, Blachly J, Byrd JC, Lapalombella R.

Leukemia · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1038/s41375-022-01758-z

Bibliografisk träff 2022-04-29

From Structure Modification to Drug Launch: A Systematic Review of the Ongoing Development of Cyclin-Dependent Kinase Inhibitors for Multiple Cancer Therapy.

Shi Z, Tian L, Qiang T, Li J, Xing Y, Ren X, Liu C, Liang C.

J Med Chem · research support, non-u.s. gov't; systematic review; journal article · DOI 10.1021/acs.jmedchem.1c02064

Bibliografisk träff 2022-04-01

First-in-Human Dose-Escalation Study of Cyclin-Dependent Kinase 9 Inhibitor VIP152 in Patients with Advanced Malignancies Shows Early Signs of Clinical Efficacy.

Diamond JR, Boni V, Lim E, Nowakowski G, Cordoba R, Morillo D, Valencia R, Genvresse I, Merz C, Boix O, Frigault MM, Greer JM, Hamdy AM, Huang X, Izumi R, Wong H, Moreno V.

Clin Cancer Res · research support, non-u.s. gov't; clinical trial, phase i; journal article · DOI 10.1158/1078-0432.ccr-21-3617

Bibliografisk träff 2021-07-15

Changing for the Better: Discovery of the Highly Potent and Selective CDK9 Inhibitor VIP152 Suitable for Once Weekly Intravenous Dosing for the Treatment of Cancer.

Lücking U, Kosemund D, Böhnke N, Lienau P, Siemeister G, Denner K, Bohlmann R, Briem H, Terebesi I, Bömer U, Schäfer M, Ince S, Mumberg D, Scholz A, Izumi R, Hwang S, von Nussbaum F.

J Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1021/acs.jmedchem.1c01000

Bibliografisk träff 2021-05-01

Targeting CDK9 for Anti-Cancer Therapeutics.

Mandal R, Becker S, Strebhardt K.

Cancers (Basel) · review-article; review; journal article · DOI 10.3390/cancers13092181

Bibliografisk träff 2020-09-28

Application of sulfoximines in medicinal chemistry from 2013 to 2020.

Han Y, Xing K, Zhang J, Tong T, Shi Y, Cao H, Yu H, Zhang Y, Liu D, Zhao L.

Eur J Med Chem · review; journal article · DOI 10.1016/j.ejmech.2020.112885

Bibliografisk träff 2020-09-17

Recent Developments in the Biology and Medicinal Chemistry of CDK9 Inhibitors: An Update.

Wu T, Qin Z, Tian Y, Wang J, Xu C, Li Z, Bian J.

J Med Chem · research support, non-u.s. gov't; review; journal article · DOI 10.1021/acs.jmedchem.0c00744